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ABSTRACT: An enzyme inhibition-based assay for drug discovery developed by
microarraing on Blu-ray disks is presented. As a proof-of-concept, the system screens a
selected molecule library of potential chemical inhibitors against the glycoenzyme
peroxidase, identifying the promising lead compounds with high selectivity using
standard Blu-ray disks and drives. In order to face the first drug discovery stages, we
establish the bases for a high-throughput screening assay and a methodology based on
hypersurfaces suitable to manage a high number of data as well.
■ INTRODUCTION
High-throughput screening (HTS) techniques for drug
discovery identify hits during primary single-point screening,
followed by lead generation using dose−response analyses.1−3
These techniques transformed drug discovery, surpassing
traditional screening methodologies and allowing researchers
to approach potential candidates in a rational manner.4,5
Although target compounds are able to display complex
concentration-dependent relationships and structure−activity
ratios, usually a single measurement at a single concentration is
taken per compound in the chemical library during a primary
drug screening.6 This working strategy results in low
performances in terms of characterizing compounds and
poor quality data.
HTS assays based on enzyme inhibition have been widely
employed for drug discovery.7−10 Most of the enzymes are
proteins that take part in a wide variety of processes inside
living organisms, such as signal transduction and cell
regulation. In this sense, several human diseases are associated
with enzyme regulation.11,12 For example, Alzheimer’s disease
is treated by the inhibition of acetylcholinesterase,13 diabetes
mellitus through the inhibition of α-glucosidase,14 or
cardiovascular diseases where the treatment is based on the
regulation of thrombin.15 Discovering new enzyme inhibitors
that treat diseases or improve those that exist in the actuality
are important for the human health point of view.16−21
We present a methodology that uses Blu-ray-based micro-
array technology (disks as assay platform and a disk-player as
detector) to perform assays for drug screening of inhibitors
against horseradish peroxidase (HRP) as a member of the
glycoenzymes superfamily.22 We establish the basis for the
development of high-throughput screening assay using
compact disk technology and develop a novel strategy based
on kinetic and thermodynamic parameters for drug discovery,
identifying hits during primary screening stages.
■ RESULTS AND DISCUSSION
Blu-ray disks have a reliable surface for creating and handling
high-density microarrays.23,24 In this article, we perform a
screening assay of inhibitors against HRP as a proof-of-concept
of the potential use of Blu-ray technology for drug screening.
For that, HRP was anchored in an oriented manner, utilizing
bioaffinity-based immobilization on Concanavalin A (ConA)
microarrays. The strong affinity of lectins (ConA) for
glycoenzymes (HRP) was employed for this purpose as this
immobilization procedure exhibited high catalytic activity and
improved stability against denaturation (see Figure S1).25
First, the relationship between the signals generated by the
activated ConA/HRP system and the ConA concentration was
established. As is shown in Figure S2B, the curve displayed a
typical pattern with no distinguishable signal at the low ConA
concentration values (i.e., not enough protein to bind HRP),
followed by an increase between 10 and 40 mg/L and a final
plateau at higher lectin values. From these data, 40 mg/L was
chosen to be the optimum ConA concentration value after
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considering that slight experimental errors in ConA steps did
not affect the signal. The results obtained with the non-
activated ConA shows that the nonspecific interaction between
ConA and HRP was not observed. This was probably because
Ca2+ and Mn2+ were absent. Indeed, these cations are essential
to allow lectin to fold in a tertiary structure that is
complementary to glycoprotein sugar residues.26
In order to select the suitable concentration of HRP to
perform the assays, the effect on the ConA/HRP signal was
recorded after developing with 3,3′,5,5′-tetramethylbenzidine
(TMB). The data are shown in Figure S2C. A linear
correlation was obtained within the concentration range
between 5 and 40, 20 mg/L being suitable for the signal
intensity requirements of the BD-player.
HRP activity was monitored from 1 to 20 min at room
temperature by time−course curves using a simple kinetic
model in an enzyme-catalyzed direct reaction (see Figure S2).
These assays were performed in the absence of TgCs as
reference for full enzymatic activity (blank). The HRP activity
is accurately obtained by 36 data points (each array containing
6 spots and 6 reaction times were analyzed), measuring the
conversion of the TMB substrate into an insoluble colored
product. The measurements were taken through reading the
BD by the disk drive, as described elsewhere.27 The obtained
data were exponentially fitted to S = SMax(1 − e(−kont)), which
provided a maximum signal value SMax = 18 300 ± 1400 (a.u.)
and a rate constant value of kon = 0.57 ± 0.14 min
−1 (R2 =
0.963). These two parameters were required to accomplish
subsequent data fittings to eq 1 in order to obtain the
inhibition parameters with maximum precision.
In order to demonstrate the concept, 12 target compounds
(TgCs) were screened for HRP activity inhibition (see the
Figure 1. Schematic theoretical model representing the process of HRP−TgC complex formation. The plots show the signal registered from
bioimmobilized HRP reaction toward TMB substrate in the presence of the target compounds at different concentrations (blank [black circle], 0.64
mM [red triangle], 1.25 mM [green diamond], 2.5 mM [blue left pointing triangle], 5 mM [pink right pointing triangle], 10 mM [yellow hexagon],
and 20 mM [orange rectangle]). Each result is the mean ± sd of 6 values and lines correspond to data fittings to eq 1.
ACS Omega Article
DOI: 10.1021/acsomega.8b03537
ACS Omega 2019, 4, 5595−5600
5596
screening criteria in Supporting Information). The large
amount of data obtained from each drug target (6
concentrations per drug, 6 different reaction times of TMB,
and 6 replicates) involved an accurate analysis of the time−
course curves to collect as much information as possible. For
that, a data fitting using a basic competitive inhibition-based
model was performed and evaluated by the Bayesian
information criterion (see Table S1). In the competitive
inhibition assay format, the inhibitor vies with the substrate for
the free enzyme, but each precludes the binding of the other.
The scheme of the model is depicted in Figure 1. This implies
that both the inhibitor and substrate bind to the active site,
which is generally true. Thus, the corresponding mathematical
expression to describe this reaction mechanism is shown in eq
1.
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where S denotes the signal obtained at a certain time (t) and
TgC concentration (C). SMax is the signal at an infinite time,
Keq is the constant of equilibrium for the TgC complex and the
free enzyme, koff is the dissociation rate constant for the TgC
complex, and kon is the rate constant for the formation of the
enzymatic product.
The inhibiting capacities of TgCs might be related to their
concentration and affinity to the native enzyme, which can be
quantified with the parameter CKeq that equals the inhibitor
concentration multiplied by the equilibrium constant. This
parameter discriminates potential inhibitors (CKeq > 0, i.e.,
favorable HRP−TgC complex formation) from noninhibitors
(CKeq ≈ 0, i.e., low HRP−TgC complex formation). Note how
low CKeq values indicate high free enzyme population on the
microarray surface, which result in high optical density
precipitates (signal). The koff parameter is a guideline of
HRP−TgC binding strength, and the possible release of TgC
from the enzymatic active site depends entirely on the nature
of the compound, and could be used to discern between
reversible (koff > 0) and irreversible (koff ≈ 0) inhibitors.
Hence, 216 data per drug target were analyzed to characterize
the enzyme inhibitor capacity of each compound in a total time
of 40 min.
The experimental inhibitor capacity and the accuracy of the
mathematical approach in reproducing the screening data are
shown in the plots of Figure 1. These inhibition parameters
(Table S2) were analyzed in an attempt to decide which of the
initial TgC selection hypotheses displayed real importance.
After evaluating the CKeq values for compounds TgC1,
TgC5, TgC7, TgC8, TgC9, and TgC11, it was ruled out that
the HRP−TgC complex was not extensively formed and the
target substance would not be considered an inhibitor. Thus,
only TgC2, TgC3, TgC4, TgC6, TgC10, and TgC12 showed
inhibition activity.
Regarding the presence of heteroatoms, the existence of a
ketonic oxygen at position 2 on the main aromatic ring did not
retrieve any inhibitory behavior (TgC1), nor when a
thioureide group (TgC11) was tested. Thus, when comparing
the inhibitory capacity of TgC1, 7−9 and 11 to the other
targeted compounds, position 2 should be occupied by a
sulphur atom in the thione form. The behaviors of TgC1 and
TgC11 were ascribed to the distinct electronegative charge
distribution for the keto−enol equilibrium in the former, and
the impossibility to achieve the corresponding thione−thiol
equilibrium in the latter. Although TgC5 had a thioureide
group at position 2, no HRP inhibition was recorded. This
could be related to the position of the ring substituent, which
might not only affect the optimal size distribution of the target
substance, but also the inefficient charge interactions of the
deprotonated carboxylic group (pKa 4.7 vs inhibition step pH
7.5) with the amino acid residues located in the enzyme cavity.
Besides, the existence of secondary amines at positions 1 and 3
on the aromatic ring was not the only requisite for binding
TgC7 to the enzyme active site, nor was there a clear effect of
the presence of a methyl residue at position 2 or 3, as occurred
with TgC8 and TgC9. The other TgC2−4, TgC6, and TgC10
compounds had a clearer inhibition effect on HRP activity
because of the presence of the preferred thione group
surrounded by secondary amines (i.e., the thioureide func-
tional group).
TgC6 was tested to ensure that the relative thioureide group
position on the aromatic ring was determinant for the
interaction with the enzyme. When compared to TgC2, an
8-fold lower inhibitory character was observed for the
equivalent experiments at the 10 mM level. Consequently,
the position of the thione atoms was concluded to be key.
The presence of propyl-(TgC3) and phenyl-(TgC4) hydro-
carbonated substituents on the thiouracil ring was also tested.
Results showed that the existence of such pendant moieties
could cause steric hindrance during the interaction of these
substances with the enzyme, which would hinder their access
to the heme cavity and, thus, their inhibitory power compared
to TgC2. The interaction seemed, however, more favorable in
TgC4 than in TgC3, which was possibly because of the affinity
of the phenyl substituent for the hydrophobic environment
inside the enzyme cavity.
HRP activity was also analyzed by considering the rigidity of
the target structure. Here, TgC10 was a less powerful inhibitor
compared to TgC4 (3-fold at 0.64 mM), which was possibly
because of the restricted spatial conformation of the phenyl
substituent (fused to the principal ring in TgC10, but
possessed higher freedom degrees in TgC4). Finally, the
substantial inhibitory power of the TgC12 compound was
explained after assuming that it possessed the predicted
thioureide functional group to bind the HRP heme site with
no steric hindrance. This conclusion was confirmed as is shown
in Figure 2, which depicts how the thiourea compound is a
powerful enzyme inhibitor, while urea is not.
In view of these data, it is possible to state that the exposed
screening process exploits the structure−activity ratios to
identify promising lead compounds. To this end, each inhibitor
candidate was defined by a three-dimensional vector, ([TgC],
[TgC] × Keq, koff). These vectors considered the concentration
([TgC] coordinate), inhibitory strength ([TgC] × Keq
coordinate), and reversibility (koff coordinate) behaviors of
any potential lead compound. Hence, this vector allows active
compounds to be identified (Keq and koff) and quantified
([TgC]) in only one assay. As mentioned above, this novel
vector greatly reduced the occurrence of outlaying data points,
and generated much more helpful data than those produced by
currently available assays. The three-dimensional vector
provided information on the structure and inhibitory
mechanism of the unknown TgC.
■ MULTIDRUG SCREENING RESULTS
In order to exploit the working capacity of Blu-ray-based
microarray technology and the versatility of the three-
ACS Omega Article
DOI: 10.1021/acsomega.8b03537
ACS Omega 2019, 4, 5595−5600
5597
dimensional vector approach, a multiple high-density micro-
array format was developed. As shown in Figure S3, 367 arrays
of different TgC solutions with four replicates each were
performed on a BD, corresponding to a total of 1468 assays
(see HTS Experimental Section in Supporting Information).
The TgC solutions were previously dropped on a polycar-
bonate (PC) plate with a pattern that matches with the arrays
of HRP immobilized on the BD surface (Figure 3A). This
suggests that, whenever required and depending on the
chemical system, a Blu-ray disk surface can be employed as a
high-density microarraying platform by covering it with over
thousands drops by simply reducing the sample volume, being
able to address multiple drug screenings and hit to lead stages.
All these data allow the characterization of multiple TgCs by
means of the three-dimensional vector. This information must
be processed properly in order to avoid tedious interpretation
process. For that, the three-dimension characterization vectors
are organized and hierarchized to display the information to
the analyst. To do this, the three-dimensional vectors were
visualized by means of a 3D graphic hypersurface (Figure 3B).
Note that the nD graphic hypersurfaces were traced if the n-
dimensional vectors were defined what might increase the
sensitivity and selectivity of the screening assay. It is also worth
mentioning that n-dimensional vectors might be achieved by
measuring more parameters. This treatment allowed the
immediate visual grouping of the targeted compounds through
the existence of peaks and valleys that enabled the easy analysis
of structural-activity ratios. Hypersurfaces locate the hotspot
areas of any biochemical system and relate them to the n-
dimensional parameters under study28 to select the most
promising lead compound.
As a proof-of-concept, we introduce the hypersurface term
using the parameters obtained in the enzyme inhibition study.
In a real situation, we should simply perform the same assay,
but the selected TgCs could be many more, such as the
hypersurface concept supports. Accordingly, Figure 3B shows
the hypersurface generated from the panel of TgCs analyzed as
bioimmobilized HRP inhibitors. This figure shows a clear peak
that was differentiated on the hypersurface located within the
CKeq and koff 0.24−47.68 and 0−0.01 min−1 ranges,
respectively. For the higher koff values, a deeper valley covered
the area to 0.520 min−1, when a new land tended to rise.
Overall, two hotspot areas were detected to be of great interest
for further research. However, the promising lead compound
was located very easily on these hypersurfaces by tracking the
maxima because this peak corresponded to the most potent
inhibitors (high Keq values). In this demonstration model, the
lead compound that predicted the drawn hypersurface was
thiourea as previously confirmed. It is possible to say that this
drug screening assay might facilitate the interpretation process,
as well as its implementation on a robotic platform for
quantitative high-throughput screening in microarray format.
■ CONCLUSIONS
We have developed an enzyme inhibition assay to test the
pharmacological potential of several compounds. The results
presented herein demonstrate that Blu-ray disk microarray
technology allows inhibitor compounds to be discriminated,
identified, characterized, and quantified in a single assay. Large
amounts of information have been obtained from small sample
volumes (more than 200 data points per drug), which have
allowed to obtain the parameters that evaluate the binding
affinity of the drug and the enzyme. The proposed method-
ology exploits the information on inhibitory strength and
reversibility behaviors of any TgC to identify promising lead
compounds.
This approach works well mainly for enzymes that directly
convert a substrate into an insoluble reaction product, but it is
possible to use indirect developers such as nanoparticles to
open the field of applications.
Our development based on Blu-ray technology is a realistic
option to optimize physicochemical and biopharmaceutical
properties in drug screening through precise measurement of
structure−activity ratios with minimal quantities of reagents
and time. Besides, its low cost (≈0.5 $/disk), widespread use,
and scan speed make the proposed methodology a powerful
versatile tool for conducting drug discovery processes, which
Figure 2. Signal registered from bioimmobilized HRP reaction toward
the TMB substrate in the absence [black square] and presence of 5
mM of urea [red circle] or 5 mM of thiourea [green triangle]. The
values are the mean of six values. Lines correspond to data fittings to
eq 1.
Figure 3. (A) Scheme depicts the protocol to create a drop pattern of
367 different TgC solutions on the Blu-ray surface. (B) Hypersurface
generated from the panel of TgCs analyzed as bioimmobilized HRP
inhibitors. koff (min
−1), [TgC] (mM) and CKeq are plotted on the X,
Y, and Z axis, respectively.
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influences both the work’s strategic direction and drives the
design of compounds for further synthesis.
■ EXPERIMENTAL SECTION
Reagents. All the buffers (printing carbonate buffer (CB):
0.015 M Na2CO3 and 0.035 M NaHCO3, pH 9.6; phosphate
saline buffer (10 mM PBS buffer, pH 7.5), prepared from 10-
fold concentrated PBS: 80 mM sodium phosphate dibasic, 15
mM potassium phosphate monobasic, 1.369 M sodium
chloride and 27 mM potassium chloride, pH 7.5; PBS-T: 10
mM PBS containing 0.05% (v/v) Tween 20 (PBS-T), pH 7.5;
citrate buffer (CitB): 25 mM monohydrate citric acid and 62
mM NaH2PO4, pH 5.5; ConA activation buffer (CAB): 100
mM Trizma base, 80 mM glycine, 3 mM CaCl2, and 3 mM
MnCl2), were prepared with purified water (18.2 MΩ × cm)
and filtered through 0.22 μm-pore sized disks (Dassel,
Germany) before use.
ConA from Canavalia ensiformis type IV, HRP from
Amoracia rusticana type VI-A, TMB liquid substrate, calcium
chloride anhydrous powder 99.99%; manganese(II) chloride
anhydrous beads 99.99%; and the enzyme inhibitors (uracil
≥99.0%, 2-thiouracil ≥99.0%, 6-n-propyl-2-thiouracil, 6-n-
phenyl-2-thiouracil ≥95%, 4-thiouracil 97%, 5-carboxy-2-
thiouracil, 2-mercaptobenzimidazole 98%, thiourea ≥99%,
imidazole ≥99%, 1-methylimidazole ≥99%, 2-methylimidazole
99%, and 2-methylthio-2-imidazoline hydriodide 99%) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). The
Blu-ray disks (BDs 25 Gbyte) were from MediaRange GmbH
(Bad Soden, Germany).
Experimental Procedure. ConA stock solution was
prepared in activation buffer (CAB) at 4 g/L and kept at
−20 °C until use. Con A coating solution (40 mg/L in CB)
was spotted (25 nL/spot) on the BDs with the noncontact
printing device AD 1500 BioDot Inc. (Irvine, CA, USA) in a
microarray format on the Blu-ray surface. To ensure
reproducible volume delivery and microprinting quality,
dispensing channel pressure, working temperature, and relative
humidity were set at steady-state values. Furthermore, the
robotic device tip was profusely washed with commercial Bio-
Terge AS40 solution (from BioDot Inc.; Irvine, CA, USA) and
purified water to ensure optimal printing to avoid cross-
contamination. The spots were 250 μm in diameter.
The coated BDs were incubated at 37 °C for 2 h to ensure
the physical immobilization (passive adsorption) of the ConA
on the surface of the Blu-ray disk.29 Then, the disk surface was
rinsed with PBS-T and distilled water. After that, 1.0 mL of
HRP solution (20 mg/L in PBS-T) was dispensed onto the
disk and homogeneously distributed using a transparent PC
dummy surface. After 30 min incubation, the disk was washed
as before. The protein-to-protein binding was characterized by
contact angle measurements using the tensile drop method
(Figure S1).
The reference activity of the enzyme was measured using a
blank solution (1:4 solution (v/v) of dimethyl sulfoxide
(DMSO)/PBS without target compound (TgC)). Finally, the
enzymatic activity was measured using TMB as a substrate.
The optical density of the generated colored precipitate was
correlated to the enzymatic activity. To perform the inhibition
assay, the TgCs were prepared in a 1:4 solution (v/v) of
DMSO/PBS within a concentration range between 0.64 and
20 mM (no influence of DMSO at 25% (v/v) on HRP activity
was detected). For that, 40 μL of TgCs were dispensed on
each array and allowed to react for 20 min at 37 °C. The disk
was then washed with deionized water and dried by
centrifugation. Finally, 1.0 mL of TMB solution was
homogeneously distributed all over the disk surface using the
dummy surface. The disk was incubated for 1−20 min at room
temperature. Finally, the disk was rinsed with deionized water
and dried by gentle shaking.
Disk Drive Imaging. The operational principle of
microarray disk reading and image analysis has been previously
reported based on the quantification of the different
reflectivities shown between sensing objects (in this case, the
TMB blue solid product generated on ConA/HRP recognition
events) located on the disk surface, and the disk surface itself.30
A standard BD-player, which operated with a laser beam λ =
405 nm, was used as the detector (LG Electronics;
Englewoods, NJ, USA). A photosensor (EE-SY125), which
included a λ = 950 nm infrared LED (Omron, Scahumburg, IL,
USA), was integrated into the device to trigger data
acquisition. A photodiode converted back-reflected light into
an analogy electrical signal that was collected and amplified by
a custom-built data acquisition board. The analogy signal
correlated to the optical density of the reaction product, that is,
analyte concentration. The BD drive’s spatial resolution and
scanning speed were monitored by the Nero Disc Speed V4
software from Nero Inc. (Glendale, CA, USA). In order to
control data acquisition (sampling rate, detector gain, etc.),
custom software (BioDisc) was used, which allowed the image
to be exported to a grey scale code to a compressed tiff or
bitmap format for data analysis.
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